[go: up one dir, main page]

MX2018003212A - Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos. - Google Patents

Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.

Info

Publication number
MX2018003212A
MX2018003212A MX2018003212A MX2018003212A MX2018003212A MX 2018003212 A MX2018003212 A MX 2018003212A MX 2018003212 A MX2018003212 A MX 2018003212A MX 2018003212 A MX2018003212 A MX 2018003212A MX 2018003212 A MX2018003212 A MX 2018003212A
Authority
MX
Mexico
Prior art keywords
reverse transcriptase
preparations
same
transcriptase inhibitors
formula
Prior art date
Application number
MX2018003212A
Other languages
English (en)
Other versions
MX391226B (es
Inventor
Mclaughlin Mark
M Milczek Erika
M Girijavallabhan Vinay
Cleator Edward
Kong Jongrock
William GIBSON Andrew
r lieberman David
Dieguez Vazquez Alejandro
Philip Keen Stephen
J Williams Michael
C Moore Jeffrey
Peng Feng
M Belyk Kevin
Jake Song Zhiguo
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2018003212A publication Critical patent/MX2018003212A/es
Publication of MX391226B publication Critical patent/MX391226B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se dirige a derivados de nucleósidos 4-substituidos de fórmula (I) y su uso en la inhibición de transcriptasa inversa de HIV, la profilaxis de infección por HIV, el tratamiento de infección por HIV y la profilaxis, tratamiento y retraso en el inicio o progresión de AIDS y/o ARC. La presente invención también proporciona procesos para la preparación de derivados de nucleósidos 4-substituidos de fórmula (I) y derivados de los mismos. (ver Fórmula).
MX2018003212A 2015-09-23 2016-09-19 Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos. MX391226B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222304P 2015-09-23 2015-09-23
US201662302452P 2016-03-02 2016-03-02
PCT/US2016/052409 WO2017053216A2 (en) 2015-09-23 2016-09-19 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof

Publications (2)

Publication Number Publication Date
MX2018003212A true MX2018003212A (es) 2018-07-06
MX391226B MX391226B (es) 2025-03-21

Family

ID=58387111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003212A MX391226B (es) 2015-09-23 2016-09-19 Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.

Country Status (10)

Country Link
US (2) US10953029B2 (es)
EP (1) EP3352781B1 (es)
JP (1) JP6768796B2 (es)
KR (1) KR102185996B1 (es)
CN (1) CN108289931B (es)
AU (1) AU2016328303B2 (es)
CA (1) CA2998646C (es)
MX (1) MX391226B (es)
RU (1) RU2720811C2 (es)
WO (1) WO2017053216A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
CN107011399B (zh) * 2017-05-24 2018-04-24 郑州职业技术学院 β构型地西他滨前体的制备方法
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
KR20210105931A (ko) * 2018-12-20 2021-08-27 머크 샤프 앤드 돔 코포레이션 Nrtti 화합물의 신규 결정질 형태
AU2020211600A1 (en) 2019-01-25 2021-07-22 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
MA55200A (fr) * 2019-03-06 2022-01-12 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
US12391694B2 (en) 2019-06-24 2025-08-19 Merck Sharp & Dohme Llc Process for the preparation of 2-fluoroadenine
AU2020320876B2 (en) * 2019-07-27 2025-09-25 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
US20220259252A1 (en) * 2019-08-08 2022-08-18 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
EP4021916A1 (en) * 2019-08-28 2022-07-06 GlaxoSmithKline Intellectual Property (No. 2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
BR112022004424A2 (pt) 2019-09-11 2022-05-31 Scripps Research Inst Pró-fármacos antivirais e formulações dos mesmos
CN112321589B (zh) * 2020-02-18 2022-05-03 山东科巢生物制药有限公司 一种抗病毒药物瑞德西韦及其中间体的合成方法
EP4121437A1 (en) * 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CA3202049A1 (en) * 2021-01-25 2022-07-28 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2022159877A1 (en) * 2021-01-25 2022-07-28 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
WO2025006582A1 (en) * 2023-06-27 2025-01-02 Gilead Sciences, Inc. Methods and intermediates for preparing antiviral prodrugs

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
HUT63170A (en) 1990-01-11 1993-07-28 Isis Pharmaceuticals Inc Process and composition for detecting and modifying rna activity and gene expression
CZ126799A3 (cs) 1996-10-16 1999-07-14 Icn Pharmaceuticals Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují
ATE250622T1 (de) 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-pyrimidine nukleoside
RU2002103501A (ru) * 1999-08-27 2003-09-10 Ай-Си-Эн Фармасьютикалз, Инк. (Us) Пирроло[2,3-d] пиримидиновые нуклеозидные аналоги
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US8481712B2 (en) * 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
SI1355916T1 (sl) * 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
AU2003237249A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
KR20050109918A (ko) * 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
RU2361875C2 (ru) 2003-06-30 2009-07-20 Айденикс (Кайман) Лимитед СИНТЕЗ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CA2637879A1 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2535345A1 (en) 2007-01-12 2012-12-19 BioCryst Pharmaceuticals, Inc. Anticancer nucleoside analogs
TW200838550A (en) 2007-02-09 2008-10-01 Novartis Ag Organic compounds
CN101835374B (zh) * 2007-07-09 2014-08-27 东弗吉尼亚医学院 具有抗病毒和抗微生物性质的取代的核苷衍生物
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
CA2705834A1 (en) * 2007-11-20 2009-05-28 Merck Sharp & Dohme Corp. Pyridinone non-nucleoside reverse transcriptase inhibitors
EA020659B1 (ru) 2008-04-23 2014-12-30 Джилид Сайэнс, Инк. 1'-замещённые карбануклеозидные аналоги для противовирусной терапии
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
JPWO2010027005A1 (ja) 2008-09-05 2012-02-02 壽製薬株式会社 置換アミン誘導体及びこれを有効成分とする医薬組成物
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
KR20110128947A (ko) 2009-03-20 2011-11-30 앨리오스 바이오파마 인크. 치환된 뉴클레오시드 및 뉴클레오티드 유사체
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
EA025252B1 (ru) 2010-07-22 2016-12-30 Гайлид Сайэнсиз, Инк. Способы и соединения для лечения вирусных инфекций paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
KR20190084350A (ko) 2012-02-03 2019-07-16 제이엔씨 주식회사 액정 화합물, 액정 조성물 및 액정 표시 소자
CN106749272B (zh) 2012-03-13 2019-08-30 吉利德科学公司 用于抗病毒治疗的2’-取代的卡巴-核苷类似物
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
US10093683B2 (en) 2014-04-22 2018-10-09 Merck Sharp & Dohme Corp. Factor XIa inhibitors

Also Published As

Publication number Publication date
MX391226B (es) 2025-03-21
JP6768796B2 (ja) 2020-10-14
CA2998646A1 (en) 2017-03-30
WO2017053216A3 (en) 2017-05-18
RU2720811C2 (ru) 2020-05-13
CA2998646C (en) 2021-05-18
KR102185996B1 (ko) 2020-12-02
WO2017053216A2 (en) 2017-03-30
AU2016328303B2 (en) 2019-05-02
AU2016328303A1 (en) 2018-03-22
JP2018532726A (ja) 2018-11-08
RU2018114463A3 (es) 2019-10-23
US20190022115A1 (en) 2019-01-24
EP3352781A4 (en) 2019-06-12
CN108289931B (zh) 2022-10-11
RU2018114463A (ru) 2019-10-23
EP3352781A2 (en) 2018-08-01
US10953029B2 (en) 2021-03-23
CN108289931A (zh) 2018-07-17
KR20180052758A (ko) 2018-05-18
EP3352781B1 (en) 2020-12-16
US20210154221A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2018003212A (es) Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
AR130699A2 (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
MX388757B (es) Profármacos de éster alifático antivíricos de tenofovir.
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
SV2018005629A (es) Compuestos antivirales de fosfodiamida de ester de beta-aminoacido
EA201590674A1 (ru) Производные 5-фенокси-3h-пиримидин-4-она и их применение в качестве ингибиторов обратной транскрипазы вич
CR20120503A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
CU24525B1 (es) Derivado de quinoleína para tratar y prevenir infecciones virales
CO2018007669A2 (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
DOP2018000183A (es) Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos
MX2016012915A (es) Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).
AR099428A1 (es) Combinaciones de principios activos farmacéuticos con compuestos basados en tri(hetero)aril pirazoles
CY1116437T1 (el) Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης
TH174353A (th) สารยับยั้งรีเวิร์สทรานสคริปเตสชนิดไม่ใช่นิวคลีโอไซด์ (Non-Nucleoside reverse transcriptase inhibitors)